A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2026.116729 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Marie Robert und 23 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Cancérologie de l'Ouest, Saint-Herblain, ARPEGO Network, France. Hauptthemen laut MEDLINE: Neoplasms, Antibodies, Monoclonal, Humanized, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut de Cancérologie de l'Ouest, Saint-Herblain, ARPEGO Network, France.
- Institut Jules Bordet, Brussels, Belgium.
- IUCT-Oncopole Claudius Régaud, Toulouse, France.
- Centre Eugène Marquis, Rennes, France.
- Institut Gustave Roussy, Villejuif, France.
- OSE Immunotherapeutics, Nantes, France.
Zitieren
APA
Robert, M., Kotecki, N., Gomez-Roca, C., Massard, C., Postel-Vinay, S., Raimbourg, J., Brandao, M., Korakis, I., Rouge, T. M., Comis, S., Imadalou, K., Chevalier, C., Cordonnier, L., Josse, C., Teppaz, G., Seité, M., Durand, J., Thepenier, V., Mary, C., …, & Cassier, P. A. (2026). A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116729
Vancouver
Robert M, Kotecki N, Gomez-Roca C, Massard C, Postel-Vinay S, Raimbourg J, et al. A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116729
BibTeX
@article{Robert2026,
author = {Robert, Marie and Kotecki, Nuria and Gomez-Roca, Carlos and Massard, Christophe and Postel-Vinay, Sophie and Raimbourg, Judith and Brandao, Mariana and Korakis, Iphigénie and Rouge, Thibaut de la Motte and Comis, Silvia and Imadalou, Karima and Chevalier, Caroline and Cordonnier, Laurie and Josse, Constant and Teppaz, Géraldine and Seité, Margaux and Durand, Justine and Thepenier, Virginie and Mary, Caroline and Gauttier, Vanessa and Derame, Mylène and Morello, Aurore and Poirier, Nicolas and Cassier, Philippe Alexandre},
title = {A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2026.116729}
}
EUVIMED